

The growing burden of antimicrobial resistance

P. M. Hawkey^{1,2*}

¹Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, UK; ²Health Protection Agency West Midlands Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham B9 5SS, UK

Since the first usage of antimicrobials, the burden of resistance among bacteria has progressively increased and has accelerated within the last 10 years. Antibiotic resistance genes were present at very low levels prior to the introduction of antibiotics and it is largely the selective pressure of antibiotic use and the resulting exposure of bacteria, not only in humans but also in companion and food animals and the environment, which has caused the rise. The increasing mobility across the globe of people, food and animals is another factor. Examples of this are the international pandemic of different genotypes of CTX-M extended-spectrum β -lactamases (particularly CTX-M-14 and -15) and the emergence of the carbapenemase KPC-1 in both the USA and Israel. This review details examples of both the emergence and dissemination through different genetic routes, both direct and indirect selective pressure, of significance resistance in *Staphylococcus aureus*, *Enterococcus* species, *Enterobacteriaceae* and *Pseudomonas/Acinetobacter*. The response made by society to reduce resistance involves surveillance, reduced usage, improved infection control and the introduction of new antimicrobial agents. Although efforts are being made in all these areas, there is an urgent need to increase the effectiveness of these interventions or some bacterial infections will become difficult if not impossible to treat reliably.

Keywords: multiresistance, antibiotic development, resistance control

The emergence, spread and globalization of antimicrobial resistance

Antibacterial therapy has only emerged over the last 60 years as a practical proposition and has become one of the pillars of modern medicine. The removal of the scourge of premature death due to bacterial infection is now taken for granted in the developed world, but this is threatened by the development of resistance to antimicrobials. As bacteria are thought to have evolved 3500 million years ago,¹ 60 years is but 'a second in a day' in evolutionary time. Despite this, we have seen the development, even since their early use, of antibiotic resistance in many bacterial species. The first description of the clinical use of penicillin was contemporaneous with a report of an enzyme (named penicillinase by the authors)—a specific member of the family of β -lactamases—that destroyed benzylpenicillin and conferred resistance to penicillin.²

Surprisingly, penicillinase production in *Staphylococcus aureus* spread rapidly, and by the late 1940s, ~50% of the *S. aureus* in the UK were positive for this trait. This was closely followed by the accumulation of resistance to penicillin, tetracycline and macrolides in the 1950s, creating strains of

S. aureus that caused considerable problems in the management of nosocomial infection. In contrast, vancomycin has been used for nearly 50 years and yet significant numbers of *S. aureus* isolates with high-level resistance are yet to emerge. Thus, the emergence of resistance to antibiotics is associated with their use, although the precise correlation can be highly variable.

The mechanisms by which antibiotic resistance can both appear *de novo* and spread among medically important bacteria are now better understood. It is clear that the horizontal gene pool, which consists of genes present on a plethora of diverse mobile genetic elements, results in the lateral transfer of genes both among strains of an individual species and among different species of both Gram-negative and Gram-positive bacteria and is the process whereby we arrive at multiresistant bacteria. The engine driving this process is the selective pressure of antimicrobial use; this is obvious in the hospital environment where clear relationships between antimicrobial use and the emergence of multiresistant strains can be seen.^{3–5} There is also increasing evidence being collected for the influence of community use of antimicrobials and in cases where reductions have been achieved in usage, reductions in resistance can be seen (e.g. reduction in penicillin resistance in pneumococci in the UK).⁶ However,

*Tel: +44-121-424-1240; Fax: +44-121-772-6229; E-mail: peter.hawkey@heartofengland.nhs.uk

more data are required to better define and describe the relationship between reducing antibiotic use and changes in resistance.

Since the publication of the Swann report in 1969, there has been recognition that the agricultural usage of antimicrobials also drives the development of resistance. The recent control of antimicrobial usage for growth promotion and mass treatment in the European Union (EU) has resulted in reductions in resistance rates, suggesting that a significant selective effect is associated with this use. Specific examples of this can be seen in countries such as Denmark and Sweden where tight control of the agricultural usage of antimicrobials has resulted in lower levels of resistance in food animals. However, we live in a global economy and the movement of people can result in the movement of multiresistant bacteria; an excellent example of this is the multiple importations of plasmidic AmpC β -lactamase-producing Enterobacteriaceae from the Indian subcontinent into one Yorkshire hospital over a 4 month period.^{7,8} The movement of people, and also food (which is increasingly screened for recognized human pathogens such as *Salmonella* and *Campylobacter*, but which is not routinely screened under current legislation for resistant commensal bacteria such as *Escherichia coli*), may well explain the movement of particular genes that have emerged in certain parts of the world and then spread. In Hong Kong, the presence of extended-spectrum β -lactamase (ESBL)-producing Gram-negative bacteria in food animals reflects the local distribution of clinical ESBL genotypes.⁹ Similarly, the presence of bacteria with characteristic ESBL genotypes in food derived from particular locations, such as chicken from Brazil carrying *E. coli* producing CTX-M-2,¹⁰ points to an increasingly important mechanism for increasing the burden of antimicrobial resistance.

The costs associated with antimicrobial resistance are multiple; inadequate or failed treatment of patients leading to morbidity and mortality is a huge human cost. In addition, the loss of cheaper, older agents for effective therapy and the need to acquire more expensive ones are easily recognized costs. However, this cost pales into insignificance when compared with the cost of the disruption of the delivery of healthcare services caused by multiple antibiotic-resistant bacteria (cost of isolation, cross-infection control and cancelled procedures) and, as this cost is not easily recognized or accounted for, it is frequently forgotten.

Emerging resistance—challenges from specific pathogens

S. aureus

Penicillinase-producing hospital strains of *S. aureus* that were also resistant to the commonly available antimicrobials, as exemplified by the phage type 80/81 strain, caused considerable clinical problems in the 1950s. These problems were solved initially by the introduction of methicillin and then by the introduction of the related semi-synthetic penicillins, cloxacillin and flucloxacillin, which resulted in a marked decline in these strains.¹¹ Very shortly after the introduction of methicillin in 1960, three resistant isolates were noted from the same hospital in southern England.¹² This marked the start of our battle with methicillin-resistant *S. aureus* (MRSA). Interestingly, despite an early surge in cases in the 1960s, MRSA rates generally fell in

Europe through to the early 1980s. The cause of this decline is not clear, but may relate to reductions in the prescribing of tetracyclines (which it has been argued were a co-selecting agent) and vigorous infection control. However, the lull was not to last for long. In the 1980s, a rise in the frequency of gentamicin-resistant MRSA was reported from the USA, Ireland and the UK.¹³ Subsequently, a series of well-characterized hospital-associated clones of MRSA have arisen. In the UK, EMRSA-15 and -16 have proved to be the dominant strains in healthcare-associated infections caused by MRSA.¹⁴ In other parts of the world, other dominant strains have emerged, and in some countries, the frequency of occurrence of MRSA among *S. aureus* exceeds 50%. Few routine surveillance data exist internationally for MRSA, but prevalence data do exist for many countries and reveal a wide variation in the prevalence of MRSA as a proportion of significant *S. aureus* isolates, ranging from <1% in countries such as the Netherlands to rates of 25% to 50% in much of the Americas, Australia and some countries in southern Europe.¹⁵ MRSA was initially thought to have arisen by a single genetic event in which a large piece of mobile DNA (the staphylococcal cassette chromosome, SCCmec) was transferred from a coagulase-negative staphylococcus into the *S. aureus* genome and inserted close to the origin of replication (*oriF*). It is now clear that this event has occurred on a number of occasions as there are multiple types of SCCmec cassette arrangements, which represent separate horizontal gene transfers. The SCCmec element has a unique mechanism of mobilization by which it excises and integrates into the new host chromosome, the element itself carrying recombinases for the cassette (*ccrAB* and *ccrC*).¹⁵

The dramatic increase in the occurrence of infections caused by MRSA led to substantially increased usage of vancomycin, but surprisingly, no resistance was seen prior to 1997. The first resistant strains identified were designated vancomycin-intermediate *S. aureus*, and these have now been reported worldwide. There is evidence that these strains have a thickened cell wall, which results in the elevation of MICs of vancomycin to 8–16 mg/L.¹⁶ The biggest fear with regard to resistance in MRSA has been the possibility of transfer of the *vanA* gene complex from glycopeptide-resistant enterococci into *S. aureus* to produce vancomycin-resistant strains (VRSA) and the rapid dissemination of the clone or clones that have acquired these genes. An early *in vitro* experiment showed that it was possible to transfer and express *vanA* in *S. aureus*,¹⁷ and between 2002 and 2007, six clinical isolates of VRSA—all carrying the *vanA* gene complex—have been reported in the USA.¹⁸ Worryingly, VRSA has also been reported from India where two strains were found in a recent survey.¹⁹ It is interesting that this event did not occur earlier or more frequently; the explanation may be the recent description of a specialized lineage-specific restriction system (*SauI* type I restriction modification system *hsdR*), which destroys incoming DNA into particular *S. aureus* lineages. Strains that have this system are unlikely to receive foreign DNA from bacteria such as enterococci, and *S. aureus* lab-strain RN4220 has a missense mutation in the *hsdR* gene that could allow gene transfer.²⁰

MRSA is usually thought of as being associated with hospitals or those who have had prolonged periods in hospital, although transmission of hospital strains among family members is well recognized. The emergence, therefore, of true community-associated strains (CA-MRSA) since the late 1990s is a further

Growing burden of antimicrobial resistance

challenge to the effective treatment of *S. aureus* infections.²¹ Early strains of CA-MRSA were initially noticed in North America where rates have now risen to as high as 70% of community-acquired *S. aureus* infections, as reported in a survey undertaken at Houston Children's Hospital.²² Outbreaks have been seen particularly among inmates in jails, but the occurrence of sometimes rapidly fatal necrotizing pneumonia, particularly among children, is of particular concern. CA-MRSA strains typically belong to different multilocus sequence typing lineages compared with the common nosocomial strains and often produce Pantone–Valentine leukocidin (PVL) toxin. The role of PVL toxin in producing the severe clinical manifestations that are seen is controversial; a recent report suggested that it may be only one of several important toxins.²³ However, more recent experiments with isogenic strains in a mouse infection model suggest that PVL is a significant virulence factor.²⁴ In contrast to the nosocomial strains, CA-MRSA strains are frequently susceptible to antimicrobials such as clindamycin, trimethoprim/sulfamethoxazole, tetracyclines, gentamicin, fluoroquinolones and chloramphenicol. However, resistance to the macrolides is common (which may also undermine the clinical efficacy of clindamycin), and there are increasing reports of resistance to older oral agents which will pose substantial problems in the future for the empirical treatment of moderate or serious *S. aureus* infections in the community.

The role of companion or agricultural animals as reservoirs for both hospital-acquired strains and CA-MRSA is increasingly recognized. A study of food animals in Korea demonstrated that a number of animal isolates of MRSA, particularly from cattle and chickens, had substantial similarities and were identical by random amplified polymorphic DNA (RAPD) typing to human isolates of nosocomial MRSA.²⁵ More recently, a particular lineage of MRSA, sequence type ST398, has been found in both companion animals and humans in Germany and Austria.²⁶ MRSA ST398 has recently been recognized, particularly in the Netherlands, as causing colonization and disease in pigs with subsequent spread to humans, emphasizing the growing importance of animals and the environment in the epidemiology of MRSA.²⁷ EMRSA-15, the dominant UK strain in nosocomial infections, has also been found as a common colonizer of both veterinary staff and companion animals.²⁸

Enterococci

Although enterococci are part of the normal gut flora and have a low virulence, colonization followed by infection can readily occur in compromised patients and those with serious injuries, particularly if they have been given selecting antibiotics. The appearance of vancomycin-resistant *Enterococcus faecium* in 1986 in the UK presaged an expansion, particularly in the USA, of a highly resistant and potentially difficult-to-treat pathogen.²⁹ Resistance to vancomycin is mediated by two major classes of gene clusters, *vanA* and *vanB*. Although problems with *vanB*-carrying vancomycin-resistant enterococci (VRE) have been reported and may be locally dominant, it is the *vanA* gene that has caused the greatest problems globally. It has been recently suggested that enterococci may have acquired the *vanA* gene by horizontal transfer from the chromosome of glycopeptide-producing *Actinomycetes*/*Streptomyces* such as *Streptomyces toyocaensis* and *Actinoplanes teichomyceticus*.³⁰ Intriguingly, *Streptomyces coelicolor*, although not a glycopeptide producer, has been found to carry *van*-like genes encoding vancomycin

resistance. It is likely that soil-inhabiting antibiotic-producing bacteria are the reservoir of *vanA*,³¹ although other investigators have suggested that *Paenibacillus* spp. may be the source.³²

Data from The Surveillance Network database indicate that during the 1990s, species-specific vancomycin resistance among isolates of *E. faecium* from blood increased rapidly in the USA from 26.2% in 1995 to 48.8% in 1996.³³ In the early days of VRE infection in hospitals, when single clonal outbreaks occurred, it was often possible to control an outbreak by prompt application of contact precautions with infected patients and screening for asymptomatic carriers of VRE. This situation still pertains in the UK. However, in the USA, it has now been found that multiclonal outbreaks, with high levels of carriage among asymptomatic patients and admissions from the community, have meant that effective control is extremely difficult; this is typified by an outbreak described at the University of Maryland Medical Centre.³⁴ The reason for the rapid and progressive spread of *E. faecium* has been hypothesized to be the agricultural use of glycopeptides such as avoparcin, the use of which was banned in the EU. Following the EU ban, there has been a significant decrease in the faecal carriage of vancomycin-resistant *E. faecium* in chickens, for example, in Denmark. However, a delay was noted in pigs due to the continued use of tylosin, which, although not a glycopeptide, nonetheless co-selects for glycopeptide resistance due to linked macrolide resistance genes.³⁵ Within the hospital environment, the use of certain antibiotics has been demonstrated to cause selection by association in case–control studies, particularly ticarcillin/clavulanate and third-generation cephalosporins.³⁶ Interestingly, the same study showed the potentially protective effect of piperacillin/tazobactam, and this effect has been confirmed in a mouse model. Mice were challenged with VRE orally, and ceftriaxone or ticarcillin/clavulanate-pre-treated animals had high levels of colonization, whereas those treated with piperacillin/tazobactam or saline were not heavily colonized.³⁷ The intensive use of oral vancomycin in hospitals for the treatment of *Clostridium difficile* infection is also likely to select for increased faecal carriage of VRE. It seems likely that a combination of good antibiotic stewardship and infection control may be the best way of controlling VRE in the hospital setting, although the influence of the veterinary use of antibiotics may continue to be felt in the European environment where there has been an increase in the VRE rates in humans.³⁸ The recent report of a substantial clonal outbreak of VRE resistant to linezolid (a critical antibiotic for the treatment of VRE) in Birmingham, AL, USA, is a cause for concern.³⁹ In the Netherlands, it has been suggested that the emergence of multidrug-resistant, hospital-adapted *E. faecium* clonal complex CC17 without a community reservoir can be explained by cross-transmission and selective antibiotic pressure and may precede the emergence of VRE.⁴⁰

Enterobacteriaceae

Following the introduction of ampicillin in the 1960s, plasmid-mediated resistance caused by the production of the TEM and SHV serine β -lactamases became a major clinical problem. A survey of *E. coli* in the faeces of patients presenting for elective surgery in West London in 1968 showed a 17% resistance rate to ampicillin, the majority of which was plasmid-mediated as demonstrated by conjugation to *E. coli* K12.⁴¹ The

development and introduction in the early 1980s of third-generation extended-spectrum cephalosporins, such as cefotaxime and ceftazidime, provided reliable therapy for patients with infections caused by Enterobacteriaceae. However, very rapidly, mutants in both the *bla*_{SHV} and *bla*_{TEM} genes were described, and these spread particularly among *Klebsiella* spp. and some strains of *E. coli*.⁴² This marked the emergence of the ESBL mutant derivatives of these widely distributed β -lactamases, which are capable of hydrolysing third-generation cephalosporins and monobactams. Their spread over the next 20 years—while extensive around the world with a lot of evidence of both convergent and divergent evolution leading to many different molecular variants—did not result in widespread problems of resistance outside the hospital environment. However, the unexpected movement of a broad-spectrum β -lactamase gene from a rare member of the Enterobacteriaceae, *Kluyvera* spp., onto broad host range plasmids, which spread initially into *E. coli* and then into *Klebsiella* and *Enterobacter* spp., has caused a much more serious problem. This family of β -lactamases is referred to as CTX-M enzymes, and more than 50 molecular variants are now described; these have either appeared or spread onto every continent with the exception of Antarctica.⁴³ Some particular genotypes appear to have emerged with a distinct geographical distribution. Arguably, the most successful enzymes are CTX-M-15, originally described in India in 2000,⁴⁴ and CTX-M-14, originally described in Guangzhou in the People's Republic of China.⁴⁵ Interestingly, CTX-M-15 has spread worldwide and is increasing rapidly in many countries and local centres. A recent study has shown it to be the only CTX-M-type ESBL present in India, where carriage rates among *E. coli* can be as high as 60%.⁴⁶ ESBL-producing strains have been clearly shown to be associated with poor patient outcome, which may well relate to inappropriate first-line treatment.⁴⁷ The risk factors for the acquisition of CTX-M ESBLs are contact with healthcare facilities (not necessarily hospitals); exposure to a range of antibiotics, including third-generation cephalosporins, trimethoprim/sulfamethoxazole and ciprofloxacin; the presence of indwelling catheters; and old age.⁴⁸ Intriguingly, the USA has been spared a major problem so far with CTX-M ESBL-producing strains of *E. coli* and *Klebsiella*, the dominant ESBLs currently in the USA being SHV and TEM types, with only a handful of reports of CTX-M ESBLs, largely from the CTX-M-1 and -9 family.⁴⁹ The Far East is particularly dominated by the CTX-M-14 and CTX-M-3 variants⁵⁰ and South America by CTX-M-9 and CTX-M-2. Eastern Europe has a particular problem with CTX-M-15, as does the UK and France, whereas Spain had a problem with CTX-M-10 and -9, which is now largely being replaced by CTX-M-14.⁴³ ESBL-producing bacteria have very high rates of resistance to fluoroquinolones, which makes treatment very difficult. It has been postulated that plasmid-mediated low-level resistance to fluoroquinolones may encourage the selection of *gyrA* mutants with high-level resistance. The two major and apparently common mechanisms of plasmid-mediated resistance are encoded by the *qnrA/B/S* and *aac(b')-Ib-cr* genes.⁵¹ The presence of multiresistance to all orally available agents is beginning to pose a considerable problem in the treatment of urinary tract infections caused by ESBL producers. The presence of *E. coli* producing CTX-M-ESBLs, particularly in the community, as has been seen in the UK, may represent one of the greatest threats to the effective treatment of Gram-negative septicaemia caused by Enterobacteriaceae.^{52,53}

When third-generation cephalosporins are used to treat infections with bacteria such as *Citrobacter* spp. and *Enterobacter* spp., high-level resistance develops in ~20% of the cases due to the over-production of the chromosomal AmpC-type β -lactamase. Subsequently, it has been found that *ampC* β -lactamase genes from a variety of Gram-negative bacteria have been mobilized onto plasmids and have spread worldwide. Although not as substantial a problem as the CTX-M-type ESBLs, these plasmid-encoded AmpC enzymes are continuing to increase in number and diversity.^{54,55} (regularly updated tables can be accessed at the Lahey web site: <http://www.lahey.org/Studies/>). When *ampC*-bearing plasmids are present in the same isolate of Enterobacteriaceae as an ESBL gene, the detection of the ESBL gene can be difficult; this requires the use of AmpC-stable cephalosporins, such as cefepime or ceftipime combined with clavulanate or boronic acid as an inhibitor, although detection is not 100% reliable even using these combinations.⁵⁶ Multiresistant Enterobacteriaceae, which are resistant to most currently available antimicrobials, are heavily treated with carbapenems, and the increased use of these carbapenems does raise fears for the development and spread of resistance. Plasmid-mediated transferable carbapenemases, mainly of the IMP and VIM families, have been described from a wide range of locations and in many different bacterial hosts, particularly in *Pseudomonas*, but they have also been described in Enterobacteriaceae.⁵⁷ The spread of KPC-2 carbapenemases among *Klebsiella pneumoniae*, *E. coli*, *Salmonella* spp. and *Enterobacter* spp. in the USA and recent reports of KPC-2- and KPC-3-producing *K. pneumoniae* from Israel suggest that we will see widespread dissemination of this gene.^{58,59}

Pseudomonas and *Acinetobacter*

Pseudomonas aeruginosa is a widespread environmental organism that can cause considerable problems in both immunocompromised patients and intensive care unit patients in hospitals where there are environmental sources. Patients who are admitted and given broad-spectrum antibiotics develop gut colonization either with their own community-acquired or nosocomially transmitted strain leading to infection in some cases. β -Lactam antibiotics such as ceftazidime and piperacillin/tazobactam have been traditionally used to treat infections, but resistance to these agents is now common in many parts of the world. The rise in quinolone resistance, not only in Enterobacteriaceae but also in *P. aeruginosa*, has further undermined the number of available agents to treat such infections, and carbapenems are used increasingly to treat *Pseudomonas* infections. Worryingly, the VIM-2 metallo-carbapenemase, which was originally described in Italy, is now widely spread across the world and has been found in substantial numbers in *Pseudomonas* spp. isolates in a number of surveys.⁶⁰ In one survey from China, the *bla*_{VIM-2} integron-associated gene was found in 14 of 140 imipenem-resistant isolates.⁶¹ Resistance to carbapenems can occur through a range of mechanisms, which include the loss of specific porins and the expression of efflux pumps, for which the *mex A/B* and *X/Y* systems are very important.⁶² A worrying survey from Canada—a country generally considered to have low levels of antibiotic resistance—of all *P. aeruginosa* isolates from the Calgary area between 2002 and 2006 revealed 14% of the strains to be resistant to imipenem. A metallo- β -lactamase phenotype was found in 35%

Growing burden of antimicrobial resistance

of those, with 96% (i.e. 178/185) positive for *bla*_{VIM} genes and the remaining 4% positive for *bla*_{IMP} genes.⁶³ Such a high incidence in a country with comparatively few problems of antibiotic resistance must indicate the possibility of the rapid spread and dissemination of these integron-associated metallo-carbapenemases elsewhere in the future.

Acinetobacter spp., particularly *Acinetobacter baumannii*, are well recognized as a cause of infection, particularly in intensive care units where their resistance to drying can pose substantial problems in their eradication from the environment. *Acinetobacter* produce a wide range of β -lactamases and have a formidable spectrum of intrinsic resistance mechanisms, which can mean that some strains are resistant to all known antibiotics with the exception of colistin.⁶⁴ The rapid spread of the OXA carbapenemases in the UK and elsewhere has eroded the activity of the carbapenems,⁶⁵ while recent reports of the development of heteroresistance to colistin in an *in vitro* pharmacokinetic/pharmacodynamic model may compromise the use of colistin as a therapeutic option.⁶⁶ Although the number of patients infected by *Acinetobacter* is small, there is a great need for novel agents that are active against these multiply resistant strains. Tigecycline has shown particular promise in this area,^{67,68} although recently decreased susceptibility has been reported in the literature.^{69,70}

Response to the increasing burden of antimicrobial resistance

The first response to high levels of antimicrobial resistance must be to reduce the selective pressure generated by antibiotic usage. As patients require treatment, it is not always possible to modify substantially or reduce antimicrobial use. However, there have been some clear examples of good antibiotic stewardship leading to reductions in antimicrobial resistance, notably the reduction in penicillin resistance among pneumococci in the UK following a 30% reduction in pharmacy sales of oral β -lactams.⁶ However, the correlation between reduced prescribing and resistance is not clear cut. The same study reported that a fall in macrolide usage was not associated with a fall in macrolide resistance. There are large numbers of studies that show a correlation between increasing usage over time of particular antimicrobial classes either with resistance to that agent or to co-selective resistance to other agents. A recent well-constructed study followed trends in antimicrobial resistance in a hospital in Taiwan over a 12 year period and concurrently collected data on usage. A rise in cefotaxime-resistant/ciprofloxacin-resistant *E. coli* and meropenem-resistant *P. aeruginosa* was significantly associated with increasing consumption of extended-spectrum cephalosporins, carbapenems, fluoroquinolones and aminoglycosides. Interestingly, increases in ciprofloxacin-resistant *K. pneumoniae* and meropenem-resistant *Acinetobacter* were significantly associated only with increased usage of extended-spectrum cephalosporins, but not with other antimicrobials.⁷¹ In contrast, some other studies have failed to show a correlation with formulary control. One such study reports the spread of ESBLs within a hospital despite antibiotic restriction, suggesting that infection control may be a better control method for antibiotic-resistant bacteria.⁷² A confounding variable in this study may have been the fact that many ESBL-producing strains were introduced from the community following admission of patients

colonized with such strains in their bowel. These strains may then have been selected following administration of a range of antimicrobials and caused endogenous infections.

In understanding the control of antibiotic-resistant bacteria, it is important to have surveillance mechanisms in place that are both accurate and comprehensive. Programmes such as EARSS (European Antimicrobial Resistance Surveillance System) and ESAC (European Surveillance of Antimicrobial Consumption) have generated data to reveal broad correlations between usage and national resistance rates and also rapid changes in patterns of resistance. Surveillance systems in the future will have to use standardized methodology, particularly in relation to susceptibility testing; the currently used range of commercial, automated and non-automated systems can generate apparently discrepant data. There are also large parts of the world where little, if any, surveillance is undertaken, and surveys supported by the pharmaceutical industry, such as SENTRY⁷³ and SMART,⁷⁴ have revealed very useful data in those parts of the world. These data suggest that antimicrobial resistance in areas where control of antimicrobial prescribing (particularly in the community) is poor is much higher. These data are confirmed by studies specifically of community isolates, for example, the occurrence of high levels of fluoroquinolone and third-generation cephalosporin resistance in community isolates of Enterobacteriaceae in China.⁷⁵

Infection control is possibly the single most important control measure that can be applied to the containment of antibiotic-resistant bacteria in a hospital setting, and there are a number of reports of successful control in the literature. One of the problems can be of making a clear case to hospital management for the deployment of scarce resources in infection control. Money spent in this area almost invariably results not just in the control of antibiotic-resistant bacteria but also in reductions in death rates.

Finally, the development and introduction of new agents have often in the past resulted in substantial reductions in the occurrence of resistance to antibiotics already in use due to the elimination of those strains that carry the resistance genes. Following the introduction of penicillin, there was a rapid rise in resistance to penicillin in *S. aureus* and other drugs such as chloramphenicol, tetracycline and erythromycin through the 1950s.¹¹ The development and widespread use of penicillinase-stable isoxazolyl penicillins such as methicillin, cloxacillin and flucloxacillin reduced the spread and occurrence of resistant strains of *S. aureus* in the 1960s. This effect was documented in a 6 year longitudinal study of the ecology of *S. aureus* in a Cincinnati hospital between 1964 and 1970.⁷⁶ The subsequent rise of MRSA presumably indirectly selected by isoxazolyl penicillins and more recently by cephalosporins and fluoroquinolones has obliterated original reductions in MRSA infections. Recently, carriage of a strain of MRSA (TW) strongly associated with intravascular device-related bacteraemia has been eradicated in ICU patients by treatment with linezolid. The authors concluded that pre-emptive treatment of carriers led to the termination of the outbreak.⁷⁷

One of the best documented examples of the phenomenon was the use of amikacin in hospitals with a high incidence of gentamicin resistance. One 3 year study demonstrated a statistically significant reduction in gentamicin resistance from 17.4% to 7.4%, with no rise in amikacin resistance.⁷⁸ In another study in which gentamicin and tobramycin were restricted and

replaced with amikacin, similar reductions were seen, which were reversed when gentamicin was re-introduced.⁷⁹ The introduction of second- and third-generation cephalosporins, which were highly active against the aminoglycoside-resistant Enterobacteriaceae, resulted in a massive reduction in hospital infections caused by them. *Serratia marcescens* frequently develops resistance to amikacin as all isolates carry a copy of the AAC(6′)-Ic aminoglycoside-inactivating enzyme resistance gene, which can become derepressed.⁸⁰ In an outbreak of *S. marcescens* cross-infection on a urology unit, heightened control of infection resources failed, but treatment of patients with second/third-generation cephalosporins was successful.⁸¹ However, this has not always been the case as sometimes a newly introduced agent will be affected by existing resistance mechanisms (e.g. resistance to cefepime in ESBL-producing *E. coli*). There are a number of novel agents either introduced or on the point of introduction that are active against Gram-positive pathogens (e.g. tigecycline, ceftobiprole, oritavancin and dalbavancin), but in the case of Gram-negative infections, the choice is much smaller with the re-introduction of some older agents, such as temocillin, which has stability to both AmpC and ESBL β-lactamases, but little activity against other pathogens such as *Pseudomonas* or stability to some other mechanisms of resistance, e.g. carbapenemases such as VIM-2.

Tigecycline was developed specifically to be unaffected by the common efflux-based mechanisms of resistance to tetracyclines, such as Tet(A/B) in Gram-negative bacteria, and those conferring ribosomal protection. In consequence, its activity is good against multiresistant *E. coli*, offering a potential new agent for ESBL/AmpC-producing multiresistant strains. The occurrence and mechanisms of resistance to tigecycline that have been reported have recently been reviewed.⁸² In a large survey of multidrug-resistant organisms in the USA, significant resistance was only seen in some isolates of *Klebsiella* (9% of *K. pneumoniae* isolates), and activity against multidrug-resistant strains was good, with no resistant *E. coli* strains reported (MIC₉₀ 0.5 mg/L and 0% resistant).⁸³ Resistance has usually been attributed to the upregulation of efflux pumps, particularly the AcrAB system.⁸² Upregulation of the AcrAB system has recently been identified in resistant isolates of *K. pneumoniae* and *Enterobacter cloacae*, with increased expression of the transcriptional regulator RamA.^{84,85} Carbapenemase-producing Enterobacteriaceae are a major emerging therapeutic problem, and in a recent survey of 104 isolates from across the globe, no resistance to tigecycline was seen.⁸⁶

Performance of tigecycline against *A. baumannii* has been generally good, and it has shown promise when used clinically.^{87,88} Resistance has been noted on a number of occasions,^{69,70,89} and recent work suggests that this is due to upregulation of the AdeABC multidrug efflux pump.⁹⁰ AdeABC efflux pumps belong to the resistance-nodulation-cell division family, which are capable of effluxing tigecycline, which is not a substrate for other efflux systems because of the glycyl substitution.⁸² A second efflux system AdeIJK has recently been identified in *A. baumannii*.⁹¹ The authors concluded on the basis of data from insertional mutants in the *adeABC* and *adeIJK* genes that both pumps contribute, in a more than additive fashion, to tetracycline and tigecycline resistance. The over-expression of AdeIJK was lethal so its precise contribution to high-level tigecycline resistance in clinical isolates is not entirely clear.⁹² The activity of tigecycline against Gram-positive

bacteria is exceptionally good. Earlier reviews of resistance in *S. aureus* (including MRSA) failed to identify any resistant strains.⁸² This finding has been confirmed by two recent surveys from the USA⁹² and Europe, Asia/Pacific, Latin and North America.⁹³ In both of the recent studies, no resistance among penicillin-non-susceptible *S. pneumoniae* and VRE was found (as judged by low MIC₉₀s as FDA/CLSI breakpoints for these organisms were not available). The useful activity against some multiresistant Gram-negative pathogens combined with very good activity against MRSA/VRE (for which no resistance has been yet reported⁸²) makes tigecycline a potentially useful agent for use in treating some nosocomial infections.

Funding

The author acknowledges the receipt of an unrestricted educational grant from Wyeth to support this work. Editorial assistance was funded by Wyeth.

Transparency declarations

This article is part of a Supplement sponsored by Wyeth. P. M. H. has received research funding from Bayer, Becton-Dickinson, MSD and Wyeth. Editorial assistance during the preparation of this manuscript was provided by Annie Jones (on behalf of Upside Endeavors, Sanatoga, USA).

References

1. Medeiros A. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. *Clin Infect Dis* 1997; **24**: S19–45.
2. Chain E, Abraham EP. An enzyme from bacteria able to destroy penicillin. *Nature* 1940; **146**: 837–42.
3. Graffunder EM, Preston KE, Evans AM *et al*. Risk factors associated with extended-spectrum β-lactamase-producing organisms at a tertiary care hospital. *J Antimicrob Chemother* 2005; **56**: 139–45.
4. Lautenbach E, Weiner MG, Nachamkin I *et al*. Imipenem resistance among *Pseudomonas aeruginosa* isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. *Infect Control Hosp Epidemiol* 2006; **27**: 893–900.
5. Martinez JA, Aguilar J, Almela M *et al*. Prior use of carbapenems may be a significant risk factor for extended-spectrum β-lactamase-producing *Escherichia coli* or *Klebsiella* spp. in patients with bacteraemia. *J Antimicrob Chemother* 2006; **58**: 1082–5.
6. Livermore DM, Reynolds R, Stephens P *et al*. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. *Int J Antimicrob Agents* 2006; **28**: 273–9.
7. Hibbert-Rogers LC, Heritage J, Gascoyne-Binzi DM *et al*. Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward. *J Antimicrob Chemother* 1995; **36**: 65–82.
8. M’Zali FH, Heritage J, Gascoyne-Binzi DM *et al*. Transcontinental importation into the UK of *Escherichia coli* expressing a plasmid-mediated AmpC-type β-lactamase exposed during an outbreak of SHV-5 extended-spectrum β-lactamase in a Leeds hospital. *J Antimicrob Chemother* 1997; **40**: 823–31.
9. Duan RS, Sit TH, Wong SS *et al*. *Escherichia coli* producing CTX-M β-lactamases in food animals in Hong Kong. *Microb Drug Resist* 2006; **12**: 145–8.

Growing burden of antimicrobial resistance

10. Warren RE, Ensor VM, O'Neill P *et al.* Imported chicken meat as a potential source of quinolone-resistant *Escherichia coli* producing extended-spectrum beta-lactamases in the UK. *J Antimicrob Chemother* 2008; **61**:504–8.
11. Parker MT. Staphylococci endemic in hospitals. *Sci Basis Med Annu Rev* 1966;157–73.
12. Colley EW, McNicol MW, Bracken PM. Methicillin-resistant staphylococci in a general hospital. *Lancet* 1965; **1**: 595–7.
13. Duckworth GJ, Lothian JL, Williams JD. Methicillin-resistant *Staphylococcus aureus*: report of an outbreak in a London teaching hospital. *J Hosp Infect* 1988; **11**: 1–15.
14. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant *Staphylococcus aureus* infection in hospitals. *J Hosp Infect* 1998; **39**: 253–90.
15. Grundmann H, Aires-de-Sousa M, Boyce J *et al.* Emergence and resurgence of methicillin-resistant *Staphylococcus aureus* as a public-health threat. *Lancet* 2006; **368**: 874–85.
16. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect* 2006; **12** Suppl 1: 16–23.
17. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS Microbiol Lett* 1992; **72**: 195–8.
18. Sung JM, Lindsay JA. *Staphylococcus aureus* that are hyper-susceptible to resistance gene transfer from enterococci. *Antimicrob Agents Chemother* 2007; **51**: 2189–91.
19. Tiwari HK, Sen MR. Emergence of vancomycin resistant *Staphylococcus aureus* (VRSA) from a tertiary care hospital from northern part of India. *BMC Infect Dis* 2006; **6**: 156.
20. Waldron DE, Lindsay JA. Sau1: a novel lineage-specific type I restriction-modification system that blocks horizontal gene transfer into *Staphylococcus aureus* between *S. aureus* isolates of different lineages. *J Bacteriol* 2006; **188**: 5578–85.
21. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant *Staphylococcus aureus* infections. *Int J Antimicrob Agents* 2006; **27**: 87–96.
22. Mishaan AM, Mason EO Jr, Martinez-Aguilar G *et al.* Emergence of a predominant clone of community-acquired *Staphylococcus aureus* among children in Houston, Texas. *Pediatr Infect Dis J* 2005; **24**: 201–6.
23. Voyich JM, Otto M, Mathema B *et al.* Is Pantone–Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant *Staphylococcus aureus* disease? *J Infect Dis* 2006; **194**: 1761–70.
24. Labandeira-Rey M, Couzon F, Boisset S *et al.* *Staphylococcus aureus* Pantone–Valentine leukocidin causes necrotizing pneumonia. *Science* 2007; **315**: 1130–3.
25. Lee JH. Methicillin (oxacillin)-resistant *Staphylococcus aureus* strains isolated from major food animals and their potential transmission to humans. *Appl Environ Microbiol* 2003; **69**: 6489–94.
26. Witte W, Strommenger B, Stanek C *et al.* Methicillin-resistant *Staphylococcus aureus* ST398 in humans and animals, Central Europe. *Emerg Infect Dis* 2007; **13**: 255–8.
27. Gaze W, O'Neill C, Wellington E *et al.* Antibiotic resistance in the environment, with particular reference to MRSA. In: Laskin I, Sarioslani S, Gadd GM, eds. *Advances in Applied Microbiology, Volume 63*. Amsterdam: Elsevier, 2008; 250–70.
28. Loeffler A, Boag AK, Sung J *et al.* Prevalence of methicillin-resistant *Staphylococcus aureus* among staff and pets in a small animal referral hospital in the UK. *J Antimicrob Chemother* 2005; **56**: 692–7.
29. Uttley AH, George RC, Naidoo J *et al.* High-level vancomycin-resistant enterococci causing hospital infections. *Epidemiol Infect* 1989; **103**: 173–81.
30. Beltrametti F, Consolandi A, Carrano L *et al.* Resistance to glycopeptide antibiotics in the teicoplanin producer is mediated by van gene homologue expression directing the synthesis of a modified cell wall peptidoglycan. *Antimicrob Agents Chemother* 2007; **51**: 1135–41.
31. Hong HJ, Hutchings MI, Neu JM *et al.* Characterization of an inducible vancomycin resistance system in *Streptomyces coelicolor* reveals a novel gene (*vanK*) required for drug resistance. *Mol Microbiol* 2004; **52**: 1107–21.
32. Guardabassi L, Perichon B, van Heijenoort J *et al.* Glycopeptide resistance vanA operons in *Paenibacillus* strains isolated from soil. *Antimicrob Agents Chemother* 2005; **49**: 4227–33.
33. Sahn DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database—USA. *Clin Infect Dis* 1999; **29**: 259–63.
34. Morris JG, Jr, Shay DK, Hebden JN *et al.* Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. *Ann Intern Med* 1995; **123**: 250–9.
35. Bager F, Aarestrup FM, Madsen M *et al.* Glycopeptide resistance in *Enterococcus faecium* from broilers and pigs following discontinued use of avoparcin. *Microb Drug Resist* 1999; **5**: 53–6.
36. Donskey CJ, Schreiber JR, Jacobs MR *et al.* A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant *Enterococcus* Surveillance Program. *Clin Infect Dis* 1999; **29**: 573–9.
37. Donskey CJ, Hanrahan JA, Hutton RA *et al.* Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant *Enterococcus faecium* in the mouse gastrointestinal tract. *J Infect Dis* 2000; **181**: 1830–3.
38. Leavis HL, Willems RJ, Top J *et al.* Epidemic and nonepidemic multidrug-resistant *Enterococcus faecium*. *Emerg Infect Dis* 2003; **9**: 1108–15.
39. Dobbs TE, Patel M, Waites KB *et al.* Nosocomial spread of *Enterococcus faecium* resistant to vancomycin and linezolid in a tertiary care medical center. *J Clin Microbiol* 2006; **44**: 3368–70.
40. Top J, Willems R, Blok H *et al.* Ecological replacement of *Enterococcus faecalis* by multiresistant clonal complex 17 *Enterococcus faecium*. *Clin Microbiol Infect* 2007; **13**: 316–9.
41. Datta N. Drug resistance and R factors in the bowel bacteria of London patients before and after admission to hospital. *Br Med J* 1969; **2**: 407–11.
42. Jacoby G, Medeiros A. More extended-spectrum β -lactamases. *Antimicrob Agents Chemother* 1991; **35**: 1697–704.
43. Canton R, Coque TM. The CTX-M β -lactamase pandemic. *Curr Opin Microbiol* 2006; **9**: 466–75.
44. Karim A, Poirel L, Nagarajan S *et al.* Plasmid-mediated extended-spectrum β -lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. *FEMS Microbiol Lett* 2001; **201**: 237–41.
45. Chanawong A, M'Zali FH, Heritage J *et al.* Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. *Antimicrob Agents Chemother* 2002; **46**: 630–7.
46. Ensor VM, Shahid M, Evans JT *et al.* Occurrence, prevalence and genetic environment of CTX-M β -lactamases in Enterobacteriaceae from Indian hospitals. *J Antimicrob Chemother* 2006; **58**: 1260–3.
47. Rodriguez-Bano J, Navarro MD, Romero L *et al.* Bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli* in the CTX-M era: a new clinical challenge. *Clin Infect Dis* 2006; **43**: 1407–14.

48. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β -lactamases. *Clin Infect Dis* 2006; **42** Suppl 4: S153–63.
49. Moland ES, Hanson ND, Black JA *et al.* Prevalence of newer β -lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. *J Clin Microbiol* 2006; **44**: 3318–24.
50. Hawkey PM. Prevalence and clonality of ESBLs in Asia. *Clin Microbiol Infect* 2008; **14** Suppl 1: 159–65.
51. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis* 2006; **6**: 629–40.
52. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. *J Antimicrob Chemother* 2005; **56**: 451–4.
53. Park CH, Robicsek A, Jacoby GA *et al.* Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* 2006; **50**: 3953–5.
54. Bauernfeind A, Chong Y, Lee K. Plasmid-encoded AmpC β -lactamases: how far have we gone 10 years after the discovery? *Yonsei Med J* 1998; **39**: 520–5.
55. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β -lactamases. *Antimicrob Agents Chemother* 2002; **46**: 1–11.
56. Song W, Bae IK, Lee YN *et al.* Detection of extended-spectrum β -lactamases by using boronic acid as an AmpC β -lactamase inhibitor in clinical isolates of *Klebsiella* spp. and *Escherichia coli*. *J Clin Microbiol* 2007; **45**: 1180–4.
57. Walsh TR. The emergence and implications of metallo- β -lactamases in Gram-negative bacteria. *Clin Microbiol Infect* 2005; **11** Suppl 6: 2–9.
58. Bratu S, Brooks S, Burney S *et al.* Detection and spread of *Escherichia coli* possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. *Clin Infect Dis* 2007; **44**: 972–5.
59. Leavitt A, Navon-Venezia S, Chmelnitsky I *et al.* Emergence of KPC-2 and KPC-3 in carbapenem-resistant *Klebsiella pneumoniae* strains in an Israeli hospital. *Antimicrob Agents Chemother* 2007; **51**: 3026–9.
60. Pallecchi L, Riccio ML, Docquier JD *et al.* Molecular heterogeneity of bla(VIM-2)-containing integrons from *Pseudomonas aeruginosa* plasmids encoding the VIM-2 metallo- β -lactamase. *FEMS Microbiol Lett* 2001; **195**: 145–50.
61. Yu YS, Qu TT, Zhou JY *et al.* Integrons containing the VIM-2 metallo- β -lactamase gene among imipenem-resistant *Pseudomonas aeruginosa* strains from different Chinese hospitals. *J Clin Microbiol* 2006; **44**: 4242–5.
62. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbiol Rev* 2006; **19**: 382–402.
63. Pitout JD, Chow BL, Gregson DB *et al.* Molecular epidemiology of metallo- β -lactamase-producing *Pseudomonas aeruginosa* in the Calgary Health Region: emergence of VIM-2-producing isolates. *J Clin Microbiol* 2007; **45**: 294–8.
64. Baker N, Hawkey P. The management of resistant *Acinetobacter* infections in the intensive therapy unit. In: Gillespie SH, ed. *Management of Multiple Drug-Resistant Infections*. Totowa, NJ: Humana Press Inc., 2004; 117–40.
65. Livermore DM, Woodford N. The β -lactamase threat in Enterobacteriaceae, *Pseudomonas* and *Acinetobacter*. *Trends Microbiol* 2006; **14**: 413–20.
66. Tan CH, Li J, Nation RL. Activity of colistin against hetero-resistant *Acinetobacter baumannii* and emergence of resistance in an *in vitro* pharmacokinetic/pharmacodynamic model. *Antimicrob Agents Chemother* 2007; **51**: 3413–5.
67. Wickens H, Warr C, Jepson A *et al.* An outbreak of multi-drug resistant *Acinetobacter baumannii* infection on an intensive care unit (ICU), and treatment with tigecycline. In: *Abstracts of 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 2006*. Abstract K-1498, p. 355. American Society for Microbiology, Washington, DC, USA.
68. Wilson P. Endemic, highly resistant *Acinetobacter* in the intensive care unit—is tigecycline the answer? In: *Abstracts of 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004*. p. 938.
69. Reid GE, Grim SA, Aldeza CA *et al.* Rapid development of *Acinetobacter baumannii* resistance to tigecycline. *Pharmacotherapy* 2007; **27**: 1198–201.
70. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 2007; **59**: 772–4.
71. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. *Int J Antimicrob Agents* 2005; **26**: 463–72.
72. Bisson G, Fishman NO, Patel JB *et al.* Extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella* species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. *Infect Control Hosp Epidemiol* 2002; **23**: 254–60.
73. PR Newswire. *SENTRY Antimicrobial Surveillance Reports Regional Resistance Patterns, Reinforces Need for Global Surveillance 1998*. <http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-15-1998/0000657993&EDATE=> (5 September 2007, date last accessed).
74. *Study Monitoring Antimicrobial Resistance Trends (SMART) 2002*. <http://www.merck.com/mrl/studies/smart.html> (7 September 2007, date last accessed).
75. Ling TK, Xiong J, Yu Y *et al.* Multicenter antimicrobial susceptibility survey of Gram-negative bacteria isolated from patients with community-acquired infections in the People’s Republic of China. *Antimicrob Agents Chemother* 2006; **50**: 374–8.
76. Phair JP, Watanakunakorn C, Goldberg L *et al.* Ecology of staphylococci in a general medical service. *Appl Microbiol* 1972; **24**: 967–71.
77. Edgeworth JD, Yadegarfar G, Pathak S *et al.* An outbreak in an intensive care unit of a strain of methicillin-resistant *Staphylococcus aureus* sequence type 239 associated with an increased rate of vascular access device-related bacteremia. *Clin Infect Dis* 2007; **44**: 493–501.
78. Ruiz-Palacios GM, Ponce de Leon S, Sifuentes J *et al.* Control of emergence of multi-resistant Gram-negative bacilli by exclusive use of amikacin. *Am J Med* 1986; **80**: 71–5.
79. Gerding DN, Larson TA. Aminoglycoside resistance in Gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. *Am J Med* 1985; **79**: 1–7.
80. Snelling AM, Hawkey PM, Heritage J *et al.* The use of a DNA probe and PCR to examine the distribution of the aac(6′)-Ic gene in *Serratia marcescens* and other Gram-negative bacteria. *J Antimicrob Chemother* 1993; **31**: 841–54.
81. Arroyo JC, Milligan WL, Postic B *et al.* Clinical, epidemiologic and microbiologic features of a persistent outbreak of amikacin-resistant *Serratia marcescens*. *Infect Control* 1981; **2**: 367–72.
82. Hawkey P, Finch R. Tigecycline: *in-vitro* performance as a predictor of clinical efficacy. *Clin Microbiol Infect* 2007; **13**: 354–62.
83. Dipersio JR, Dowzicky MJ. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycolcycline antimicrobial. *Int J Antimicrob Agents* 2007; **29**: 518–27.

Growing burden of antimicrobial resistance

84. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in *Enterobacter cloacae*. *Microb Drug Resist* 2007; **13**: 1–6.
85. Ruzin A, Visalli MA, Keeney D *et al*. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2005; **49**: 1017–22.
86. Castanheira M, Sader HS, Deshpande LM *et al*. Antimicrobial activity of tigecycline and other broad spectrum antimicrobials tested against serine carbapenemase- and metallo- β -lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother* 2008; **52**: 570–3.
87. Coelho JM, Turton JF, Kaufmann ME *et al*. Occurrence of carbapenem-resistant *Acinetobacter baumannii* clones at multiple hospitals in London and Southeast England. *J Clin Microbiol* 2006; **44**: 3623–7.
88. Taccone FS, Rodriguez-Villalobos H, De Backer D *et al*. Successful treatment of septic shock due to pan-resistant *Acinetobacter baumannii* using combined antimicrobial therapy including tigecycline. *Eur J Clin Microbiol Infect Dis* 2006; **25**: 257–60.
89. Peleg AY, Potoski BA, Rea R *et al*. *Acinetobacter baumannii* bloodstream infection while receiving tigecycline: a cautionary report. *J Antimicrob Chemother* 2007; **59**: 128–31.
90. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in *Acinetobacter calcoaceticus*–*Acinetobacter baumannii* complex. *J Antimicrob Chemother* 2007; **59**: 1001–4.
91. Damier-Piolle L, Magnet S, Bremont S *et al*. AdeIJK, a RND pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007; **52**: 557–62.
92. Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant Gram-positive organisms across the census regions of the United States and *in vitro* activity of tigecycline, a new glycolcyclycline antimicrobial. *Am J Infect Control* 2007; **35**: 521–6.
93. Reinert RR, Low DE, Rossi F *et al*. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the *in vitro* activity of tigecycline. *J Antimicrob Chemother* 2007; **60**: 1018–29.